Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

• Male or eligible female participants

• Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)

• Moderate to severe COPD, defined as

‣ A clinically documented history of COPD for at least 1 year

⁃ A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (\<)0.70 and a post-salbutamol FEV1 greater than (\>)30 percent (%) and \<80% predicted normal values

• Elevated risk for exacerbations, defined as

‣ A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and

⁃ The presence of risk factors for future exacerbations/deterioration such as:

⁃ Modified Medical Research Council (mMRC) dyspnea score \>= 2

⁃ COPD Assessment Test (CAT) \>= 15

⁃ Post-bronchodilator FEV1 \< 50% predicted

⁃ Chronic bronchitis

• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening.

• Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist \[LABA\] or LABA+ Long-acting muscarinic receptor antagonist \[LAMA\]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months

• Body mass index (BMI) \>=16 kilograms per square meter (kg/m\^2)